Bridge Laboratories has announced that it has reached an agreement to build its second preclinical facility in China.
This purpose built, 150,000 square foot facility will be adjacent to Bridge's existing laboratory in the Zhongguancun Life Science Park located in Beijing, China.
Construction of the new laboratory will begin in the fourth quarter of 2008. This state-of-the-art facility, expected to be completed in late fourth quarter 2009 and designed to meet the United States Food and Drug Administration and worldwide regulatory standards, will provide GLP toxicology, immunology, vaccine, and bioanalytical services. This new facility will quadruple Bridge's available laboratory space in Beijing.
"Bridge is committed to providing quality preclinical services to our customers, and this new facility will enable us to expand our ability to deliver US-level regulatory compliant outsourced discovery and development services in a cost effective manner," said Tom Oakley, president and CEO, Bridge Laboratories. "China is becoming a very attractive solution to many multinational pharmaceutical and biotech companies – We have an established presence and are prepared to meet the growing requirements for preclinical services. We are looking forward to using this new facility to expand our relationships with our current customers and to build relationships with new customers who are looking for high-quality, lower cost alternatives for their preclinical development needs," Oakley continued.
Bridge Laboratories is a US-owned, preclinical contract research organization that provides US-level regulatory compliant drug development services globally. Bridge is headquartered in Gaithersburg, Maryland, with AAALAC accredited lab facilities in the US and Beijing, China. Bridge is known for its extensive work in toxicology; including vaccines, developmental and reproductive toxicology, and safety pharmacology. Bridge's facility in China was among the first labs to perform GLP studies for clients worldwide.
